Oncology Institute (DFPH) EBIT Margin (2021 - 2026)

Oncology Institute (DFPH) has reported EBIT Margin for 6 consecutive years, with 4.42% the latest figure, recorded in Q1 2026.

• EBIT Margin for Q1 2026 came in at 4.42%, up 508.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 5.99% (up 692.0% YoY), and the FY2025 annual result was 7.18%, up 810.0% from the prior year.
• EBIT Margin was 4.42% for Q1 2026 at Oncology Institute, up from 4.87% in the prior quarter.
• Over five years, EBIT Margin peaked at 4.42% in Q1 2026 and troughed at 43.14% in Q1 2023.
• Average EBIT Margin over 5 years is 18.91%, with a median of 16.97% recorded in 2023.
• The widest YoY moves for EBIT Margin: up 4295 bps in 2022, down 2988 bps in 2022.
• Over 5 years, EBIT Margin stood at 35.11% in 2022, then jumped by 49 bps to 17.82% in 2023, then soared by 33 bps to 11.9% in 2024, then soared by 59 bps to 4.87% in 2025, then advanced by 9 bps to 4.42% in 2026.
• Per Business Quant data, the three most recent EBIT Margin figures were 4.42% in Q1 2026, 4.87% in Q4 2025, and 5.9% in Q3 2025.